Stock AGN ARGENICA THERAPEUTICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Argenica Therapeutics Limited

Equities

AGN

AU0000150328

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 02:10:44 2024-04-26 am EDT 		5-day change 1st Jan Change
0.565 AUD +0.89% Intraday chart for Argenica Therapeutics Limited -0.88% +10.78%
Apr. 16 Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy MT
Apr. 12 Argenica Therapeutics Raises AU$12 Million via Placement MT

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Argenica Therapeutics Limited

Euroz Hartleys Adjusts Argenica Therapeutics’ Price Target to AU$1.40 From AU$1.50, Keeps at Speculative Buy MT
Argenica Therapeutics Raises AU$12 Million via Placement MT
Argenica Therapeutics Doses First Batch of Patients for Phase Two Stroke Trial MT
Argenica Therapeutics Doses First Patient in Phase Two Stroke Trial; Shares Rally 14% MT
FDA Grants Argenica Rare Pediatric Disease Designation for Hypoxic Ischaemic Encephalopathy Treatment; Shares Up 16% MT
Argenica Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Argenica Therapeutics Concludes Manufacturing, Release Testing for Stroke Drug; Shares Rise 3% MT
Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024 MT
Argenica Therapeutics Appoints Nonexecutive Chair MT
Argenica Therapeutics Limited Announces Changes to its Board, Effective 1 December 2023 CI
Argenica Therapeutics Secures US FDA Orphan Drug Designation for Neurological Medication MT
Argenica Therapeutics Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023 MT
Argenica Therapeutics Limited Announces the Resignation of Dr. Samantha South as Executive Director Effective 30 November 2023 CI
Argenica Therapeutics' Drug Candidate Reduces Brain Injury in Hypoxic-Ischemic Encephalopathy Preclinical Model MT
Argenica Therapeutics Secures Ethics Approval for Phase 2 Stroke Trial MT
Argenica Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Preclinical Data Shows Argenica Therapeutics' ARG-007 Able to Mitigate Neurodegenerative Disorders MT
Argenica Therapeutics Files Ethics Application for Phase Two Stroke Trial MT
Argenica Therapeutics Validates Efficacy of Neuroprotective Drug in Preclinical Trial MT
22,625,752 Ordinary Shares of Argenica Therapeutics Limited are subject to a Lock-Up Agreement Ending on 11-JUN-2023. CI
8,300,000 Options of Argenica Therapeutics Limited are subject to a Lock-Up Agreement Ending on 9-JUN-2023. CI
Argenica Therapeutics Raises AU$4 Million for Phase Two Trial MT
Argenica Therapeutics Confirms Effectivity of Neuroprotective Medication in Preclinical Study; Shares Fall 5% MT
Argenica Therapeutics Validates Safety Profile of Neuroprotective Drug MT
Argenica Therapeutics Limited Releases Safety Data for its Phase 1 Clinical Trial of ARG-007 in Healthy Human Volunteers CI

Chart Argenica Therapeutics Limited

Chart Argenica Therapeutics Limited
More charts

Company Profile

Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).
Sector
Biotechnology & Medical Research
Calendar
2024-08-20 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ARGENICA THERAPEUTICS LIMITED Stock Argenica Therapeutics Limited
+10.78% 45.25M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. AGN Stock
  4. News Argenica Therapeutics Limited
  5. Argenica Therapeutics On Track for First Patient Dosing in Phase 2 ARG-007 Trial in Q1 2024